NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

Nevro NVRO is well-poised for growth in ... However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist. This Zacks Rank #3 ...

A new development in spinal cord injury treatment is offering new hope for those facing life-altering mobility challenges ...

Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...

The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment ...

Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Wednesday, March 19 based on AAII’s Stock Grades.

Sacral neuromodulation, in which electrical pulses from an implanted device help control the bladder, was found to ease symptoms in MS.

In 2022, the brain implants market was valued at over USD 5.7 billion, and its rapid expansion is fueled by several key factors. One of the most significant drivers is the rising incidence of nervous ...